Related early screening tools save millions of lives each year, whereasMicrosoftEfforts are being made to make it a reality. The tech giant announced Thursday it is working with Adaptive Biotechnologies, a Seattle-based biotechnology company, for a multi-year project to establish a comprehensive blood test that can decode dozens or even hundreds of hundreds of species by decoding the information in the immune system disease.
As part of the deal, Microsoft is investing an undisclosed amount in Adaptive and providing the company's cloud computing and machine learning services. Chad Robins, chief executive of Adaptive Biotechnologies, said the combined value of both is hundreds of millions of dollars. The project is part of the Microsoft Healthcare NExT program, which aims to use Microsoft technologies to solve medical problems.
The system our body uses to detect and eliminate the disease is called the adaptive immune system and it will detect the disease better than ever before. All the information our immune system knows is encoded as genes for immune cells, such as T cells and B cells, that float in our bloodstream. Adaptive Biotechnologies uses a technique called next-generation sequencing to read the genes of these cells and create an immune spectrum of billions of data points. There is plenty of data buried somewhere in the area, a sign of any disease that is brewing.